Purpose: We are seeking patients with Narcolepsy (Type 1 or Type 2) who are interested in switching from high-sodium oxybate (XYREM) to low-sodium oxybate (XYWAV) to participate in a study. This study aims to assess how this medication change impacts blood pressure. The reduced sodium content in XYWAV compared to XYREM may lower blood pressure, potentially decreasing the risk of hypertension and other cardiovascular diseases.

Inclusion: NT1 or NT2 on high-sodium oxybate, 18-70 years old, high blood pressure

Exclusion: Unstable medical/psychiatric conditions, cardiovascular disease, substance use disorder, specific genetic conditions. 

Commitment:

• 11 weeks, 6-8 visits at Redwood City Sleep Clinic. 
• 24-hour blood pressure monitoring, urine collection, sleep and dosing diaries
• Compensation: up to $1,625

Contact: Miran Cho: mirancho@stanford.edu  

If you're interested in the study and would like more information, please scan the QR code or click here to complete the questionnaire. We’ll contact you if you qualify.

Purpose: DUET is an open-label study to investigate the effects of XYWAV on sleepiness, polysomnography, and functional outcomes in participants with Idiopathic Hypersomnia (IH) or Narcolepsy (Type 1 or Type 2). This is measured through the completion of daily questionnaires, surveys, and change in polysomnogram measurements before and after treatment with XYWAV.

Inclusion: NT1/NT2 already taking 9 grams of XYWAV, 18-75 years old

Exclusion: Various medical/psychiatric conditions, pregnant, shift workers, planning to travel across more than 3 time zones during the study.

Commitment:

• 10-21 weeks, clinic and virtual visits, overnight in-lab sleep studies, daily diaries. 
• participants will receive an active dose of XYWAV at no cost.
• Compensation: up to $3,400. 

Contact: Reetu Joshi: rgjoshi@stanford.edu  

If you're interested in the study and would like more information, please scan the QR code or click here to complete the questionnaire. We’ll contact you if you qualify.

Purpose: This phase 3 study is testing the safety and efficacy of the compound TAK-861 in NT1. TAK-861 is a selective orexin-2 agonist and is designed to reduce daytime narcolepsy symptoms by restoring orexin signaling in the brain

Inclusion: Diagnosis of NT1, 16-70 years old, BMI 18-40 kg/m²

Commitment:

• Narcolepsy medication washout
• 3 overnight sleep studies
• 3 daytime sleep studies
• 5 daytime clinic visits
• 2 days of 25-hr blood pressure monitoring
• Daily e-diaries
• Compensation: $1,179 - $1,603

Contact: Reetu Joshi: rgjoshi@stanford.edu  

If you're interested in the study and would like more information, please scan the QR code or click here to complete the questionnaire. We’ll contact you if you qualify.

Purpose: A long-term extension study to test the safety/efficacy of the compound TAK-861 in participants with Narcolepsy Type 1

Inclusion: Completed participation in previous Takeda OX2R study (TAK-861-2001, TAK-861-3001) with no persisting severe adverse events from the compound.

Commitment

• First 3 months: in-clinic morning appointments once every 2 weeks
• 3-9 months: in-clinic morning appointments once every month
• One overnight PSG/daytime MWT
• After a year: in-clinic appointments once every 3 months until FDA approval of the compound
• Compensation: $2,560

Contact: Reetu Joshi: rgjoshi@stanford.edu

Purpose: We are looking for participants with Narcolepsy Type 1 to evaluate the usefulness of the Dreem 3 System headband to help diagnose and manage excessive sleepiness(hypersomnia) disorders. The Dreem 3S Headband is a new device intended to diagnose and monitor sleep disorders.

Inclusion: NT1 who will washout narcolepsy medication, ≤18 years old. 

Exclusion: pregnant, shift workers, history of stoke/epilepsy, implanted hypoglossal nerve stimulator or AHI 3% >15 not adherent to positive airway pressure therapy, not willing to reduce/stop the medications taking for narcolepsy during the study

Commitment:

• Total of 4-5 visits up to 2 weeks including  
• 6-day medication washout 
• 7 nights wearing Dreem at-home 
• Completing questionnaires and sleep diaries 
• 2 overnight in-lab sleep studies 
• 1 daytime in-lab sleep study 
• Compensation: up to $2,000 

Contact: Miran Cho: mirancho@stanford.edu

If you're interested in the study and would like more information, please scan the QR code or click here to complete the questionnaire. We’ll contact you if you qualify.

Purpose: We are looking for participants with Narcolepsy (Type 1 or Type 2) to evaluate safety and efficacy of ALKS 2680 in NT1 and NT2. ALKS 2680 is a selective orexin-2 receptor agonist that aims to restore orexin signaling, and, thereby promote wakefulness and ameliorate cataplexy in patients with NT1/NT2.

Inclusion: NT1 or NT2 

Commitment:

• 2-week medication washout 
• 2 overnight visits, up to 9 in-clinic visits, up to 12 virtual visits 
• Questionnaires, blood samples, actigraphy monitoring, sleep/cataplexy diaries
• Compensation: up to $2250 - $3350

Contact: Taylor Yoo: tjnyoo@stanford.edu

If you're interested in the study and would like more information, please scan the QR code or click the links to complete the questionnaire. We’ll contact you if you qualify.

For NT1

For NT2